De Castro M, Orive G, Hernández R M, Gascón A R, Pedraz J L
Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria-Gasteiz, Spain.
J Microencapsul. 2005 May;22(3):303-15. doi: 10.1080/026520405000099893.
Alginate-poly-L-lysine (PLL)-alginate microcapsules have been widely used in cell microencapsulation technology. However, the mechanical fragility and low tensile resistance against swelling of this membrane chemistry and the difficult handling, immunogenicity and cytotoxicity of PLL have stimulated the study of novel polycations. In this paper, alginate microcapsules coated with three different polycations: poly-L-lysine (PLL), poly-D-lysine (PDL) and poly-L-ornithine (PLO) were fabricated to evaluate if the use of novel membrane chemistries (PDL, PLO) had a positive effect on the morphology, osmotic resistance and mechanical stability of the capsules as well as the viability of the immobilized C2C12 myoblast cells when compared to the classical PLL microcapsules. Results indicate that liquefied capsules presented worse mechanical properties than the polymerized solid capsules in the three type of membrane chemistries. In addition, PLL membrane chemistry exerted the highest resistance against compressions after culture in several mediums, while PDL microcapsules showed the highest resistance to the tensile stress of the osmotic pressure. No important differences were detected when the physiological activity of the enclosed cells was evaluated. In summary, although further in vivo assays are needed, in general none of the new membrane formulations represented a significant improvement over classical PLL microcapsules.
海藻酸盐-聚-L-赖氨酸（PLL）-海藻酸盐微胶囊已广泛应用于细胞微囊化技术。然而，这种膜化学的机械脆性、对肿胀的低拉伸抗性以及PLL难以处理、免疫原性和细胞毒性激发了对新型聚阳离子的研究。本文制备了涂覆有三种不同聚阳离子（聚-L-赖氨酸（PLL）、聚-D-赖氨酸（PDL）和聚-L-鸟氨酸（PLO））的海藻酸盐微胶囊，以评估与经典的PLL微胶囊相比，新型膜化学（PDL、PLO）的使用是否对微胶囊的形态、抗渗性和机械稳定性以及固定化C2C12成肌细胞的活力产生积极影响。结果表明，在三种膜化学类型中，液化微胶囊的机械性能比聚合的固体微胶囊差。此外，在几种培养基中培养后，PLL膜化学对压缩的抗性最高，而PDL微胶囊对渗透压的拉伸应力表现出最高的抗性。在评估包封细胞的生理活性时未检测到重要差异。总之，虽然需要进一步的体内试验，但一般来说，新的膜制剂与经典的PLL微胶囊相比没有显著改进。
